Certara, Inc. (NASDAQ:CERT) Shares Bought by Geneva Capital Management LLC

Key Points

• Geneva Capital Management LLC increased its holdings in Certara, Inc. by 3.9%, acquiring 213,089 shares in the first quarter, bringing its total ownership to 5,671,689 shares valued at $56.15 million.
• Other institutional investors have also adjusted their positions, with notable increases from Versant Capital Management (up 218.8% in Q1) and Wells Fargo (up 48.4% in Q4).
• Analyst ratings for Certara indicate a consensus of "Moderate Buy" with a target price of $15.29, showcasing mixed upgrades and downgrades from various financial institutions.

Geneva Capital Management LLC grew its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 3.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,671,689 shares of the company's stock after buying an additional 213,089 shares during the quarter. Geneva Capital Management LLC owned 3.51% of Certara worth $56,150,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Versant Capital Management Inc raised its position in shares of Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after purchasing an additional 1,866 shares during the period. Wells Fargo & Company MN boosted its position in Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after buying an additional 1,047 shares during the period. Johnson Financial Group Inc. acquired a new stake in Certara during the 4th quarter worth approximately $47,000. Sterling Capital Management LLC lifted its position in shares of Certara by 57.2% in the 4th quarter. Sterling Capital Management LLC now owns 7,209 shares of the company's stock worth $77,000 after purchasing an additional 2,624 shares during the period. Finally, Portside Wealth Group LLC bought a new stake in shares of Certara in the 1st quarter valued at $104,000. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Stock Performance

Shares of NASDAQ:CERT traded down $0.32 during trading on Friday, hitting $10.94. The stock had a trading volume of 1,486,716 shares, compared to its average volume of 1,738,564. Certara, Inc. has a 12-month low of $8.64 and a 12-month high of $15.69. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of 218.84 and a beta of 1.42. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.27. The stock has a 50-day simple moving average of $10.94 and a two-hundred day simple moving average of $11.78.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%. The business had revenue of $104.57 million for the quarter, compared to analyst estimates of $104.14 million. During the same period in the previous year, the company earned $0.07 earnings per share. The company's quarterly revenue was up 12.1% compared to the same quarter last year. On average, equities research analysts expect that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on CERT. Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $11.00 to $14.00 in a research note on Thursday, May 8th. Robert W. Baird lifted their price target on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. JMP Securities restated a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. KeyCorp dropped their price target on Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. Finally, UBS Group lowered their price objective on Certara from $17.50 to $15.00 and set a "buy" rating for the company in a research report on Thursday. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Certara presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.14.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.